Asgard Therapeutics appoints Martin Bonde as Independent Chair of the Board of Directors

Asgard Therapeutics appoints Martin Bonde as Independent Chair of the Board of Directors

Asgard Therapeutics, a biotech company pioneering in vivo direct reprogramming approaches for cancer immunotherapy, today announces the appointment of Martin Bonde as independent Chair of its Board of Directors. Martin Bonde has more than 25 years of international experience from the biotech industry, in executive and board positions. Asgard is a member of SmiLe Incubator.

Martin Bonde will succeed Lars Hedbys, who served as Chair of the Board since January 2021 and will continue as a non-executive independent director.

“We are delighted to welcome Martin Bonde as Independent Chair at Asgard as we transition to the next step as a drug development company. Martin brings a wealth of international experience in biotech, insights into building successful companies and boards, and a commitment to advancing innovative therapies for cancer patients. We look forward to working together and advance the preclinical studies of our proprietary in-vivo reprogramming strategies. I also wish to take this occasion to thank Lars Hedbys for his essential and invaluable contribution in the first steps of spinning-out a company from Lund University and evolving to a VC-backed company,” says Cristiana Pires, PhD, Co-Founder and CEO of Asgard Therapeutics.

Currently, Martin Bonde is CEO of Swiss-based oncology company Inthera Bioscience AG. Prior to this, he has held several leadership positions as CEO including Vaccibody AS (now Nykode Therapeutics AS, Euronext Growth Oslo:VACC), Epitherapeutics Aps (sold to Gilead Sciences, Inc.), NatImmune A/S (sold to Azanta A/S), Combio A/S (sold to Arpida AG), Torsana Biosensor (sold to Celtor Bioscience, Inc.), and Osteometer Biotech (now Nordic Bioscience A/S).


Photo: Martin Bonde, Chair of the Board, and Fábio Rosa, Cristiana Pires and Filipe Pereira, co-founders of Asgard Therapeutics.

SmiLe Incubator